Pre-Open Stock Movers 08/12: (CYCC) (SGI) (ACIA) Higher; (ORIG) (CXRX) (XCOM) Lower (more...)

August 12, 2016 9:28 AM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Today's Pre-Open Stock Movers

Ocean Rig UDW (NASDAQ: ORIG) 53% LOWER; Said "Given the ongoing distressed market environment as well as the consensus view that a recovery may not occur for several years, we have engaged financial and legal advisors to assess the viability of our capital structure and alternatives that may be available to pursue."

Cyclacel Pharmaceuticals (NASDAQ: CYCC) 35.3% HIGHER; H.C. Wainwright maintained a Buy rating with a price target of $60. Analyst Andrew Fein sees positive risk/reward, as it pending AML readout may be detracting from valuation.

SGI (NASDAQ: SGI) 28% HIGHER; signed a definitive agreement to be acquired by Hewlett Packard Enterprise (NYSE: HPE) for $7.75 per share in cash, a transaction valued at approximately $275 million, net of cash and debt.

Acacia Communications (NASDAQ: ACIA) 23.6% HIGHER; reported Q2 EPS of $0.43, versus $0.09 reported last year. Revenue for the quarter came in at $116.2 million, versus $57.9 million reported last year. GUIDANCE: Acacia Communications sees Q3 2016 EPS of $0.64-$0.76. Acacia Communications sees Q3 2016 revenue of $120-128 million.

Concordia Healthcare (NASDAQ: CXRX) 22.7% LOWER; reported Q2 EPS of $1.38, $0.04 worse than the analyst estimate of $1.42. Revenue for the quarter came in at $231.7 million versus the consensus estimate of $229.76 million. CFO resigns, lowers outlook and suspended dividend.

Xtera Communications (NASDAQ: XCOM) 22% LOWER; reported Q3 EPS of ($1.35), versus ($4.24) reported last year. Revenue for the quarter came in at $15.35 million, versus $16.17 million reported last year.

voxeljet AG (NYSE: VJET) 17.9% LOWER; reported Q2 EPS of (EUR0.46), versus (EUR0.54) reported last year. Revenue for the quarter came in at EUR6.3 million, versus EUR5.5 million reported last year. Business Outlook - We decreased our full year 2016 guidance of revenues from between kEUR 28,000 and kEUR 30,000 to between kEUR 24,000 and kEUR 25,000 for the Group.

Eleven Biotherapeutics (NASDAQ: EBIO) 17.3% HIGHER; reported Q1 EPS of ($0.33), versus ($0.36) reported last year. Revenue for the quarter came in at $277 thousand, versus $114 thousand reported last year.

Pernix Therapeutics (NASDAQ: PTX) 15.4% LOWER; reported Q2 EPS of ($0.47), versus ($0.62) reported last year. Revenue for the quarter came in at $36.75 million, versus $46.98 million reported last year. Brean Capital downgraded from Buy to Hold.

Delek US Holdings (NYSE: DK) 14.2% HIGHER; CVR Energy (NYSE: CVI), controlled by Carl Icahn, is preparing to make an offer for Delek US Holdings (NYSE: DK), according to the New York Post. Icahn may also be building a personal stake in Delek.

Sunrun (NASDAQ: RUN) 13% HIGHER; reported Q2 EPS of $0.31, $0.71 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $122.5 million versus the consensus estimate of $111.15 million.

Nordstrom (NYSE: JWN) 11.3% HIGHER; reported Q2 EPS of $0.67, $0.11 better than the analyst estimate of $0.56. Revenue for the quarter came in at $3.65 billion versus the consensus estimate of $3.68 billion. Comps were down 1.2%.

Anavex Life Sciences (NASDAQ: AVXL) 7% HIGHER; reported Q3 EPS of ($0.06), versus ($0.22) reported last year. The SEC staff recently advised Company’s legal counsel that the staff did not intend to recommend enforcement action by the Commission against the Company in connection with the investigation previously described in the Company’s 2015 Report on Form 10-K.

Ruby Tuesday (NYSE: RT) 6.7% LOWER; reported Q4 EPS of $0.10, $0.01 worse than the analyst estimate of $0.11. Revenue for the quarter came in at $279.3 million versus the consensus estimate of $285 million. Comps declined 3.7%. GUIDANCE: Ruby Tuesday sees FY2017 EPS of $0.05-$0.09, versus the consensus of $0.13.

Itron (NASDAQ: ITRI) 6% HIGHER; reported Q1 EPS of $0.44, versus $0.22 reported last year. Revenue for the quarter came in at $498 million, versus $446.75 million reported last year.

InvenSense (NYSE: INVN) 4.7% HIGHER; Pacific Crest upgraded from Sector Weight to Overweight with a price target of $9.

Dillard's (NYSE: DDS) 3.5% LOWER; reported Q2 EPS of $0.35, $0.04 better than the analyst estimate of $0.31. Revenue for the quarter came in at $1.45 billion versus the consensus estimate of $1.48 billion. Sales in comparable stores for the period decreased 5%.

NVIDIA (NASDAQ: NVDA) 3.4% HIGHER; reported Q2 EPS of $0.53, $0.16 better than the analyst estimate of $0.37. Revenue for the quarter came in at $1.43 billion versus the consensus estimate of $1.35 billion.

Viavi (NASDAQ: VIAV) 3.1% LOWER; reported Q4 EPS of $0.10, $0.01 better than the analyst estimate of $0.09. Revenue for the quarter came in at $224.1 million versus the consensus estimate of $220.39 million. GUIDANCE: Viavi sees Q1 2017 revenue of $201-217 million, versus the consensus of $212.1 million. Sees non-GAAP earnings per share to be $0.06 to $0.08, versus the consensus of $0.08.

Planet Fitness (NYSE: PLNT) 2.8% HIGHER; reported Q2 EPS of $0.17, versus $0.00 reported last year. Revenue for the quarter came in at $91.5 million, versus $78.95 million reported last year. GUIDANCE: Planet Fitness sees FY2016 EPS of $0.63-$0.66. Planet Fitness sees FY2016 revenue of $366-372 million.

Radius Health (NASDAQ: RDUS) 2.2% HIGHER; continued takeover chatter

J.C. Penney (NYSE: JCP) 1.2% HIGHER; reported Q2 EPS of ($0.05), $0.10 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $2.92 billion versus the consensus estimate of $2.93 billion. Comps rose 2.2 percent, versus a 2.2 percent gain expected by analysts.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Special Reports

Related Entities

Carl Icahn, Pacific Crest Securities, Earnings, Pre-Open Losers, Pre-Open Winners, Pre Market Movers, H.C. Wainwright, Brean Capital

Add Your Comment